Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Irvingia gabonensis, commonly known as African mango, has garnered interest for its potential effects on components of metabolic syndrome, including obesity, dyslipidemia, and insulin resistance. Several small clinical trials have investigated extracts of Irvingia gabonensis seeds (often branded as IGOB131) in overweight or obese individuals. Some of these studies report modest reductions in body weight, waist circumference, and improvements in blood lipid profiles and markers of glycemic control after supplementation for periods ranging from 4 to 12 weeks. For example, a 2009 randomized controlled trial (Oben et al., Lipids in Health and Disease) found that participants receiving Irvingia gabonensis extract lost more weight and improved their cholesterol and blood glucose levels compared to placebo. However, the overall quality of the evidence is low: most studies are small, short-term, and sometimes sponsored by supplement manufacturers. There is a lack of large, independent, long-term trials confirming efficacy and safety. Additionally, while some traditional uses of the plant exist (mainly as a food and for treating other ailments), its use specifically for metabolic syndrome is based on recent scientific exploration rather than longstanding traditional medicine. In summary, there is some preliminary scientific evidence suggesting Irvingia gabonensis may support aspects of metabolic syndrome, but this evidence is currently limited and not robust enough to warrant strong conclusions or widespread clinical use.

More about Irvingia gabonensis
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Irvingia gabonensis

Products containing Irvingia gabonensis